Biotech Stock Mailbag: More Amarin, MannKind, Orexigen

BOSTON ( TheStreet) -- Welcome to the end of a crazy week. Some of you are still dealing with the lack of electricity or damage caused by Hurricane Sandy, but here's hoping the weekend starts to bring some relief.

This week's Biotech Stock Mailbag is a continuation of Tuesday's live chat. About 1,200 readers posted 390 comments and questions on a thoughtful variety of biotech stocks. A great turnout and much appreciated. Unfortunately, it was only possible for me to publish and respond to a fraction of those questions. (I published or answered 17% of the comments and questions sent to me Tuesday, to be precise.)

Let's see if I can improve upon that response rate today.

Amarin ( AMRN) was definitely the most queried biotech stock during Tuesday's live chat.

Patrick writes: "Amarin is a definite takeout, not sure if the price will be in the mid-20s, though."

Bravo33: "You mentioned in commentary back in June that getting NCE for Amarin was more important than its targeted patents. That seems counterintuitive. Do you still hold that belief?"

The five years of market exclusivity that comes with New Chemical Entity (NCE) status and long-lived patents are important. The mistake Amarin bulls made was the belief that the NCE decision (or lack thereof) was insignificant.

Without NCE, Amarin can expect genetic drug makers to quickly file a challenge to Vascepa patents. Generic makers could also try to develop a prescription-grade fish-oil compound that works around Amarin's patents. It's true that these things could happen even if FDA grants Vascepa NCE status, but the timeline is accelerated without NCE. That's why the current NCE mess/delay has weighed heavily on Amarin's stock price.

David comments: "The new AstraZeneca ( AZN) CEO suspended the stock buyback. Many believe he won't waste much time in putting that cash to use to address the dearth of AstraZeneca's late-stage assets. Forest Labs ( FRX) is seen by some as a fit, Amarin potentially as well. Thoughts?"

We've seen a lot of speculation linking Amarin to a number of Big Pharma suitors, not just AstraZeneca. I can't sit here and say a deal will never happen, but at the same time, I'll remind you that Big Pharma tends to buy assets with maximum market exclusivity and long-lived patents. Patent expirations and generic competition are the reasons many Big Pharma companies are in trouble today, so the last thing they'll do today is buy a drug with a high risk of generic challenge.

MP asks: "How do you know Amarin patents are not important for NCE decision?"

Because I've read the FDA regulations explaining how the NCE decision is made. The decision boils down to whether the active moiety of a drug has received FDA approval previously. Patents don't play a role in the decision:

This is how FDA defines active moiety:

"The molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt (including a salt with hydrogen or coordination bonds), or other non-covalent derivative (such as a complex, chelate, or clathrate) of the molecule, responsible for the physiological or pharmacological action of the drug substance."

Vascepa's active moiety is EPA -- same as GlaxoSmithKline's ( GSK) Lovaza. Since Lovaza was previously approved and granted NCE status, FDA cannot grant NCE status to Vascepa. It doesn't matter that EPA concentrations and purity are higher in Vascepa than Lovaza, or that Amarin has granted patents on Vascepa.

FDA can make exceptions or Amarin can appeal a negative decision. My guess is the delay in making a final ruling on NCE since Vascepa was approved in July is due to the latter.

Zbyrnes asks: "Any theories behind the VascepaNCE delay, particularly if the reasoning for a pending denial is so cut-and-dry?"

Yes, see above for an explanation.

Patrick states: "NCE is becoming less important with all the patents. Amarin will end up getting scooped."

Groman100: "Well, Adam, it looks like no one cares what you think." He also predicts, "Amarin will prove you wrong; NCE is a go."

Guest writes: "Completely agree on NCE but still believe Vascepa has huge market potential and should be very attractive for an acquistion."

We'll see. Hopefully, Amarin pulls back the curtain a bit on Vascepa's future when the company reports third-quarter results. At this point, we all deserve a bit more clarity.

John writes: " Vivus ( VVUS) only got NME, not NCE, and it is doing fine."

True, Qsymia combines two generically available medicines so it was not eligible for the five years of market exclusivity as an NCE. Instead, FDA granted Vivus three years of market exclusivity to Qsymia as a New Molecular Entity. I take issue with your assertion that Qsymia is doing fine. The weight-loss drug's launch has been a disappointment, even if it's still in the early stages.

I don't believe NCE/NME status has played a significant role in Qsymia's launch, but notice that Vivus launched the drug on its own. No Big Pharma partner. Amarin doesn't have a partner either -- yet.

Synds: "Has MannKind ( MNKD) found its bottom?"

I don't call stock bottoms. The most positive thing I can say about MannKind is the recent financings give the company enough cash to fund operations through the end of the Afrezza phase III trials expected mid-2013, perhaps longer.

Taking a step back from the fiscal cliff doesn't seem like sufficient reason to own MannKind but you may disagree. Fundamentally, MannKind is still a mess. The balance sheet is a travesty, with close to 380 million fully diluted shares outstanding, $128 million in debt and a $215 million in open convertible notes. The company continues to survive only due to the irrational largesse of founder Al Mann. No partner has stepped forward to legitimize Afrezza, probably because Mann is the only person who believes diabetics need or want an inhaled insulin device.

I understand there may be trading opportunities in MannKind, especially as we get closer to Afrezza's data release in mid-2013, but don't overlook the enormous regulatory, commercial and financial challenges still in the company's path.

NK writes: "I am interested in Orexigen Therapeutics ( OREX)."

I'm interested in Orexigen, too, because Contrave might just be the Goldilocks of weight-loss pills.

Goldilocks picks up the big red bowl of porridge (Qsymia) that belongs to Papa Bear (Vivus) but it's much too hot to eat. Goldilocks then picks up the blue bowl of porridge (Belviq) that belongs to Mama Bear ( Arena Pharmaceuticals ( ARNA)), but it's too cold. Finally, Goldilocks finds a yellow bowl of porridge (Contrave) that belongs to Baby Bear (Orexigen.) She tastes the porridge, and it's just right. Not too hot, not too cold. It's delicious, and she eats the entire bowl.

Chris asks: "Do you think Isis Pharmaceuticals ( ISIS) can get CHMP approval for Kynamro?"

Yes, I can see European regulators approving Kynamro (mipomersen) but, like in the U.S., only for the narrow homozygous familial hypercholesterolemia (HoFH) patient population. Efforts to expand Kynamro's label to treat a broader (and less fatal) forms of high cholesterol is going to be very challenging given the drug's safety issues.

Alex: "What do you think about Osiris Therapeutics ( OSIR)? Earnings next week!"

Prochymal was approved for sale by Canadian regulators in May. Will Osiris ever get around to launching the drug or generating revenue? I won't hold my breath. More likely, Osiris CEO Randy Mills will use next week's conference call to blow more smoke. Remember, Mills works for Peter Friedli and his Swiss investor friends.

Several readers on Tuesday's live chat asked about Dyax ( DYAX) and Exact Sciences ( EXAS). Answers next week, I promise!

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat